Firms affiliated with the Neurotechnology Industry Organization expressed concern over the FDA's failure to meet some drug-approval deadlines and to schedule discussions with companies. Such delays and the agency's tight focus on product safety can slow down drug development for as long as six months, said Ron Cohen, CEO of Acorda Therapeutics. The firm plans in early 2009 to seek FDA approval for Fampridine-SR, a treatment for multiple sclerosis.

Related Summaries